Aziz Mottiwala - Mar 5, 2025 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Mar 5, 2025
Transactions value $
$0
Form type
4
Date filed
3/7/2025, 04:19 PM
Previous filing
Mar 19, 2024
Next filing
Mar 18, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Stock Option (right to buy) Award $0 +33.7K $0.00 33.7K Mar 5, 2025 Common Stock 33.7K $44.54 Direct F1
transaction TARS Restricted Stock Units Award $0 +22.1K $0.00 22.1K Mar 5, 2025 Common Stock 22.1K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the option shares shall vest on March 5, 2026, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, subject to the Reporting Person's continuous service.